Clariant Opens New Innovation Center in Frankfurt - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Clariant Opens New Innovation Center in Frankfurt



Untitled Document

Clariant, a provider of fine and specialty chemicals, has opened its new EUR 100 million ($134 million) Clariant Innovation Center (CIC) in Frankfurt, Germany. The company’s new global hub for R&D is based at the “Industriepark Höchst.” It will be the home of Clariant’s competence centers in chemical research and process technology as well as application laboratories for several business units and analytical laboratories. The CIC will also house the departments for Intellectual Property Management and New Business Development. As the corporation’s global hub, the CIC will coordinate Clariant’s R&D network, which includes centers across Europe, North America, Brazil, Japan, India, and China. The new facility covers a total surface area of 36,000 m2 and will house around 500 employees from R&D and support business and administrative functions. It features a mix of open workspaces, offices, and laboratories.

Source: Clariant

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here